Disappointing news for potential new treatment for Alzheimer’s

Canada

The Alzheimer Society of Canada is disappointed to hear that, after reviewing data from Phase 3 clinical trials, a U.S. Food and Drug Administration (FDA) advisory panel did not find conclusive evidence that a potential new treatment for Alzheimer’s was effective at reducing cognitive decline.

MRI images.

Download this article as a PDF.

Aducanumab, a drug developed by Biogen and Eisai, will now go back to the FDA for a final decision on its approval

This is frustrating news for the more than half a million Canadians living with Alzheimer's disease or another type of dementia, as they are in desperate need of new and better treatments and a cure. Said to slow decline in memory and thinking skills in adults with mild cognitive impairment (MCI), aducanumab represents the most promising treatment for Alzheimer’s in nearly two decades. Should there be subsequent trials, the Alzheimer Society will advocate that study participation continues to include Canadians.

Alzheimer Society of Canada calls for increased investment into groundbreaking research

This news is a stark reminder of the vital need for increased investment in research into Alzheimer’s and other dementias, which remains the most underfunded of all major diseases. To increase the chances of a breakthrough, it is vital that dementia research receives more funding.

The Alzheimer Society continues to support groundbreaking dementia research in Canada through initiatives such as the Alzheimer Society Research Program (ASRP), which to date has invested over $64 million in Canadian researchers. This year alone, we’ve provided $2.4 million to support 21 projects across the country. However, 80 more projects had to be turned away due to lack of funds, despite these projects making it through our rigorous, peer-reviewed qualification process.

It is with increased investment in research that the Alzheimer Society can support additional projects that can advance our knowledge of dementia and improve the quality of life for people living with the disease.

Learn more about the research we fund or make a donation.

Media contact

Email: pr@alzheimer.ca

Tel: 416-488-8772 

Toll-free: 1-800-616-8816 

What is the process for approving dementia drugs in Canada?

Many people ask us how new dementia drugs are approved in Canada. In short, these drugs go through the same regulatory process that any other drug does. Here is more information about how drugs are approved in Canada – and which medications have made the grade for major dementias so far.

Learn more
Alzheimer Drugs Pills

The Alzheimer Society Research Program

The Alzheimer Society Research Program is one of Canada's most innovative hubs for dementia research, helping the brightest minds in the field spark their work from idea to impact. Since 1989, we have invested over $78 million in grants and awards toward innovative dementia research nationally.

Learn more
Three scientists in labcoats consult with each other